Trial Site Detail
Drug: |
BIIB021 (CNF2024) |
|||
|---|---|---|---|---|
Trial: |
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Completed |
|||
Memorial Sloan Kettering1275 York Ave |
Principal Investigator: |
Robert Maki, MD |
|---|---|
Contact: |
|
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Memorial Sloan Kettering Website: |
http://www.mskcc.org/mskcc/html/2270.cfm?Tab=All |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.